Relapses contribute significantly to the risk of plasmodium vivax infection and disease in papua new guinean children 1-5 years of age

Journal of Infectious Diseases

Volumn 206, Issue 11, 2012, Pages 1771-1780

  Betuela, Inoni ^a,b   Rosanas Urgell, Anna ^a,b   Kiniboro, Benson ^a   Stanisic, Danielle I ^a,d   Samol, Lornah ^a   De Lazzari, Elisa ^b   Del Portillo, Hernando A ^b,c   Siba, Peter ^a   Alonso, Pedro L ^b   Bassat, Quique ^b   Mueller, Ivo ^a,b,d  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; PLACEBO; PRIMAQUINE;

APICOMPLEXAN LIFE CYCLE STAGE; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPNOZOITE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NONHUMAN; PAPUA NEW GUINEA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REINFECTION; RELAPSE;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; PAPUA NEW GUINEA; PRIMAQUINE; RECURRENCE; RISK FACTORS; TIME FACTORS;

EID: 84869059007     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis580     Document Type: Article

References (46)

1. Phimpraphi W, Paul RE, Yimsamran S, et al. Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. Malar J 2008; 7:99.
2. Maitland K, Williams TN, Bennett S, et al. The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo Island, Vanuatu. Trans R Soc Trop Med Hyg 1996; 90:614-20.
3. Michon P, Cole-Tobian JL, Dabod E, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 2007; 76:997-1008.
4. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001; 64:97-106.
5. Earle WC. Epidemiology of malaria in Puerto Rico. Puerto Rico J Pub Health Trop Med 1939; 15:3-27.
6. Balfour MC. Malaria studies in Greece. Am J Trop Med Hyg 1935; 15:301-29.
7. Muller I, Bockarie M, Alpers M, Smith T. The epidemiology of malaria in Papua New Guinea. Trends Parasitol 2003; 19:253-9.
8. Senn N, Rarau P, Stanisic D, et al. Efficacy of intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax. PLoS Med 2012; 9:e1001195.
9. Lin E, Kiniboro B, Gray L, et al. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One 2010; 5:e9047.
10. Kasehagen LJ, Mueller I, McNamara DT, et al. Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg 2006; 75:588-96.
11. Mueller I, Widmer S, Michel D, et al. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar J 2009; 8:41.
12. Muller I, Genton B, Rare L, et al. Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J 2009; 8:158.
13. Genton B, D'Acremont V, Rare L, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 2008; 5:e127.
14. Hii JL, Smith T, Vounatsou P, et al. Area effects of bednet use in a malaria-endemic area in Papua New Guinea. TransRSocTropMedHyg 2001; 95:7-13.
15. Benet A, Mai A, Bockarie F, et al. Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in Papua New Guinea. Am J Trop Med Hyg 2004; 71:277-84.
16. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011; 10:297.
17. Lee YC, Tang CS, Ang LW, Han HK, James L, Goh KT. Epidemiological characteristics of imported and locally-acquired malaria in Singapore. Ann Acad Med Singapore 2009; 38:840-9.
18. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336-45.
19. WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: World Health Organization, 2010.
20. Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33:713-26.
21. Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008; 359:2545-57.
22. Baird JK. Real-world therapies and the problem of vivax malaria. N Engl J Med 2008; 359:2545-47.
23. Falk N, Maire N, Sama W, et al. Comparison of PCR-RFLP and Genescan- based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg 2006; 74:944-50.
24. Schoepflin S, Valsangiacomo F, Lin E, Kiniboro B, Mueller I, Felger I. Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J 2009; 8:250.
25. Mueller I, Schoepflin S, Smith TA, et al. The force of infection: key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A. In press.
26. Bretscher MT, Maire N, Chitnis N, Felger I, Owusu-Agyei S, Smith T. The distribution of Plasmodium falciparum infection durations. Epidemics 2011; 3:109-18.
27. Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malar J 2006; 5:122.
28. WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva, Switzerland: World Health Organisation, 2008.
29. Koepfli C, Mueller I, Marfurt J, et al. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis 2009; 199:1074-80.
30. Barnadas C, Koepfli C, Karunajeewa HA, Siba PM, Davis TME, Mueller I. Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistanceassociated markers. Antimicrob Agents Chemother 2011; 55:4479-81.
31. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195:927-33.
32. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 2007; 195:934-41.
33. Genton B, Al Yaman F, Beck HP, et al. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasitol 1995; 89:359-76.
34. Rosanas-Urgell A, Mueller D, Betuela I, et al. Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J 2010; 9:361.
35. Müller I, Genton B, Rare L, et al. Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J 2009; 8:158.
36. Ehrman F, Ellias J, Young M. Plasmodium vivax Chesson strain. Science 1945; 101:377.
37. Craige B, Alving AS, Jones R, Merrill Whorton C, Pullman TN, Eichelberger L. The Chesson strain of Plasmodium vivax malaria. II. Relationship between prepatent period, latent period and relapse rate. J Infect Dis 1947; 80:228-36.
38. Imwong M, Boel ME, Pagornrat W, et al. The first Plasmodium vivax relapses of life are usually genetically homologous. J Infect Dis 2012; 205:680-3.
39. Koepfli C, Ross A, Kiniboro B, et al. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis 2011; 5:e1424.
40. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg 2004; 70:642-4.
41. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009; 22:508-34.
42. Alonso PL, Brown G, Arevalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8:e1000406.
43. A research Agenda for Malaria eradication: drugs. PLoS Med 2011; 8: e1000402.
44. Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128.
45. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009; 48:1704-12.
46. The malERA Consultative Group on Diagnoses and Diagnostics (2011) A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics. PLoS Med 8 (1):e1000396.